Chargement en cours...
The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin
Sodium glucose co-transporter (SGLT-2) inhibitor is a relatively new medication used to treat diabetes. At present, the Food and Drug Administration (FDA) has only approved three medications (canagliflozin, dapagliflozin and empagliflozin) in this drug class for the management of Type 2 diabetes. In...
Enregistré dans:
| Publié dans: | Oxf Med Case Reports |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Oxford University Press
2016
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4962888/ https://ncbi.nlm.nih.gov/pubmed/27471597 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/omcr/omw061 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|